-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text | Tom Lee
Facing the competition from Bristol-Myers Squibb, Amgen’s inflammatory drug Otezla is stepping up to consolidate its position in the field of psoriasis
At the same time, Amgen also submitted a supplementary new drug application (sNDA) for the oral drug Otezla in February this year.
According to the National Psoriasis Foundation, approximately 125 million people worldwide suffer from psoriasis, accounting for 2% to 3% of the total population
Amgen’s Discreet trial used a modified sPGA-G assessment as the primary endpoint of the trial, which tracks the severity of genital psoriasis
A total of 289 patients with Otezla or placebo were enrolled in the Discreet Phase III study
The new test data gives Otezla a chance to gain recognition from the psoriasis community again
However, Mizuho analyst Salim Syed recently warned in an investor report that the future development of Otezla may be in jeopardy
The results of the study confirmed that compared with placebo, more patients achieved a psoriasis area and severity index improvement of at least 75% after receiving a 6 mg dose of deucavacitinib once a day for 16 weeks, and patients' skin lesions were reduced to sPGA 0/1
According to data released by Amgen last month, Otezla's sales in the third quarter of 2021 increased by 13% to $609 million
Reference source: Amgen's Otezla notches win in genital psoriasis, snagging possible edge against forthcoming BMS rival
